nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Simvastatin—atherosclerosis	0.107	0.199	CbGbCtD
Trametinib—CYP2C8—Pravastatin—atherosclerosis	0.105	0.195	CbGbCtD
Trametinib—CYP2C8—Lovastatin—atherosclerosis	0.105	0.195	CbGbCtD
Trametinib—CYP3A4—Rosuvastatin—atherosclerosis	0.0466	0.0867	CbGbCtD
Trametinib—CYP3A4—Ezetimibe—atherosclerosis	0.0466	0.0867	CbGbCtD
Trametinib—CYP3A4—Simvastatin—atherosclerosis	0.0433	0.0806	CbGbCtD
Trametinib—CYP3A4—Pravastatin—atherosclerosis	0.0424	0.0789	CbGbCtD
Trametinib—CYP3A4—Lovastatin—atherosclerosis	0.0424	0.0789	CbGbCtD
Trametinib—Hyperkeratosis—Niacin—atherosclerosis	0.00589	0.0309	CcSEcCtD
Trametinib—Rhabdomyolysis—Rosuvastatin—atherosclerosis	0.00261	0.0137	CcSEcCtD
Trametinib—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00234	0.0123	CcSEcCtD
Trametinib—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00225	0.0118	CcSEcCtD
Trametinib—Rhabdomyolysis—Lovastatin—atherosclerosis	0.00222	0.0116	CcSEcCtD
Trametinib—Rhabdomyolysis—Ezetimibe—atherosclerosis	0.00217	0.0114	CcSEcCtD
Trametinib—Bone disorder—Ezetimibe—atherosclerosis	0.00213	0.0112	CcSEcCtD
Trametinib—Rash pustular—Niacin—atherosclerosis	0.00211	0.0111	CcSEcCtD
Trametinib—Rhabdomyolysis—Simvastatin—atherosclerosis	0.00207	0.0109	CcSEcCtD
Trametinib—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00202	0.0106	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Lovastatin—atherosclerosis	0.00196	0.0103	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Ezetimibe—atherosclerosis	0.00192	0.0101	CcSEcCtD
Trametinib—Rhabdomyolysis—Niacin—atherosclerosis	0.0019	0.00999	CcSEcCtD
Trametinib—Rhabdomyolysis—Pravastatin—atherosclerosis	0.00187	0.00983	CcSEcCtD
Trametinib—Bone disorder—Niacin—atherosclerosis	0.00186	0.00978	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Niacin—atherosclerosis	0.00185	0.00972	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Simvastatin—atherosclerosis	0.00183	0.00963	CcSEcCtD
Trametinib—Renal failure acute—Rosuvastatin—atherosclerosis	0.00182	0.00955	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Pravastatin—atherosclerosis	0.00166	0.0087	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Lovastatin—atherosclerosis	0.00164	0.00859	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Ezetimibe—atherosclerosis	0.0016	0.00842	CcSEcCtD
Trametinib—Rash maculo-papular—Niacin—atherosclerosis	0.00153	0.00803	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Simvastatin—atherosclerosis	0.00153	0.00803	CcSEcCtD
Trametinib—Pain in extremity—Lovastatin—atherosclerosis	0.00142	0.00747	CcSEcCtD
Trametinib—Pancreatitis—Rosuvastatin—atherosclerosis	0.00142	0.00747	CcSEcCtD
Trametinib—Pain in extremity—Ezetimibe—atherosclerosis	0.0014	0.00733	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Pravastatin—atherosclerosis	0.00138	0.00726	CcSEcCtD
Trametinib—Renal failure acute—Pravastatin—atherosclerosis	0.0013	0.00684	CcSEcCtD
Trametinib—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00126	0.0066	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00126	0.0066	CcSEcCtD
Trametinib—Haematuria—Rosuvastatin—atherosclerosis	0.00123	0.00648	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00123	0.00646	CcSEcCtD
Trametinib—Pancreatitis—Lovastatin—atherosclerosis	0.00121	0.00633	CcSEcCtD
Trametinib—Pancreatitis—Ezetimibe—atherosclerosis	0.00118	0.00621	CcSEcCtD
Trametinib—Abdominal discomfort—Lovastatin—atherosclerosis	0.00118	0.00619	CcSEcCtD
Trametinib—Pancreatitis—Simvastatin—atherosclerosis	0.00113	0.00592	CcSEcCtD
Trametinib—Dry skin—Niacin—atherosclerosis	0.00112	0.00588	CcSEcCtD
Trametinib—Dry skin—Pravastatin—atherosclerosis	0.0011	0.00579	CcSEcCtD
Trametinib—Abdominal discomfort—Simvastatin—atherosclerosis	0.0011	0.00579	CcSEcCtD
Trametinib—Infestation NOS—Ezetimibe—atherosclerosis	0.00108	0.00565	CcSEcCtD
Trametinib—Infestation—Ezetimibe—atherosclerosis	0.00108	0.00565	CcSEcCtD
Trametinib—Urinary tract infection—Lovastatin—atherosclerosis	0.00107	0.0056	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00106	0.00557	CcSEcCtD
Trametinib—Arrhythmia—Rosuvastatin—atherosclerosis	0.00104	0.00545	CcSEcCtD
Trametinib—Pancreatitis—Pravastatin—atherosclerosis	0.00102	0.00535	CcSEcCtD
Trametinib—Mental disorder—Rosuvastatin—atherosclerosis	0.00102	0.00534	CcSEcCtD
Trametinib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000951	0.00499	CcSEcCtD
Trametinib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000949	0.00498	CcSEcCtD
Trametinib—Stomatitis—Niacin—atherosclerosis	0.000918	0.00482	CcSEcCtD
Trametinib—Urinary tract infection—Pravastatin—atherosclerosis	0.000901	0.00473	CcSEcCtD
Trametinib—Chills—Lovastatin—atherosclerosis	0.000883	0.00464	CcSEcCtD
Trametinib—Cough—Rosuvastatin—atherosclerosis	0.000882	0.00463	CcSEcCtD
Trametinib—Angiopathy—Ezetimibe—atherosclerosis	0.000876	0.0046	CcSEcCtD
Trametinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00087	0.00457	CcSEcCtD
Trametinib—Arthralgia—Rosuvastatin—atherosclerosis	0.000861	0.00452	CcSEcCtD
Trametinib—Myalgia—Rosuvastatin—atherosclerosis	0.000861	0.00452	CcSEcCtD
Trametinib—Haemoglobin—Niacin—atherosclerosis	0.00085	0.00446	CcSEcCtD
Trametinib—Mental disorder—Ezetimibe—atherosclerosis	0.000846	0.00444	CcSEcCtD
Trametinib—Haemorrhage—Niacin—atherosclerosis	0.000846	0.00444	CcSEcCtD
Trametinib—Malnutrition—Ezetimibe—atherosclerosis	0.000841	0.00441	CcSEcCtD
Trametinib—Erythema—Ezetimibe—atherosclerosis	0.000841	0.00441	CcSEcCtD
Trametinib—Dysgeusia—Lovastatin—atherosclerosis	0.000839	0.00441	CcSEcCtD
Trametinib—Oedema peripheral—Niacin—atherosclerosis	0.000833	0.00437	CcSEcCtD
Trametinib—Back pain—Lovastatin—atherosclerosis	0.000829	0.00435	CcSEcCtD
Trametinib—Chills—Simvastatin—atherosclerosis	0.000826	0.00434	CcSEcCtD
Trametinib—Muscle spasms—Lovastatin—atherosclerosis	0.000824	0.00432	CcSEcCtD
Trametinib—Infection—Rosuvastatin—atherosclerosis	0.00082	0.0043	CcSEcCtD
Trametinib—Back pain—Ezetimibe—atherosclerosis	0.000813	0.00427	CcSEcCtD
Trametinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000809	0.00425	CcSEcCtD
Trametinib—Muscle spasms—Ezetimibe—atherosclerosis	0.000808	0.00424	CcSEcCtD
Trametinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000808	0.00424	CcSEcCtD
Trametinib—Vision blurred—Lovastatin—atherosclerosis	0.000808	0.00424	CcSEcCtD
Trametinib—Mental disorder—Simvastatin—atherosclerosis	0.000807	0.00423	CcSEcCtD
Trametinib—Erythema—Simvastatin—atherosclerosis	0.000802	0.00421	CcSEcCtD
Trametinib—Eye disorder—Niacin—atherosclerosis	0.00079	0.00415	CcSEcCtD
Trametinib—Dysgeusia—Simvastatin—atherosclerosis	0.000785	0.00412	CcSEcCtD
Trametinib—Anaemia—Ezetimibe—atherosclerosis	0.000777	0.00408	CcSEcCtD
Trametinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000773	0.00406	CcSEcCtD
Trametinib—Muscle spasms—Simvastatin—atherosclerosis	0.000771	0.00405	CcSEcCtD
Trametinib—Angiopathy—Niacin—atherosclerosis	0.000767	0.00403	CcSEcCtD
Trametinib—Leukopenia—Lovastatin—atherosclerosis	0.000767	0.00403	CcSEcCtD
Trametinib—Chills—Niacin—atherosclerosis	0.000759	0.00398	CcSEcCtD
Trametinib—Vision blurred—Simvastatin—atherosclerosis	0.000756	0.00397	CcSEcCtD
Trametinib—Arrhythmia—Niacin—atherosclerosis	0.000755	0.00396	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000752	0.00395	CcSEcCtD
Trametinib—Chills—Pravastatin—atherosclerosis	0.000747	0.00392	CcSEcCtD
Trametinib—Insomnia—Rosuvastatin—atherosclerosis	0.000747	0.00392	CcSEcCtD
Trametinib—Arrhythmia—Pravastatin—atherosclerosis	0.000744	0.0039	CcSEcCtD
Trametinib—Anaemia—Simvastatin—atherosclerosis	0.000741	0.00389	CcSEcCtD
Trametinib—Malnutrition—Niacin—atherosclerosis	0.000736	0.00386	CcSEcCtD
Trametinib—Erythema—Niacin—atherosclerosis	0.000736	0.00386	CcSEcCtD
Trametinib—Cough—Ezetimibe—atherosclerosis	0.000734	0.00385	CcSEcCtD
Trametinib—Myalgia—Lovastatin—atherosclerosis	0.00073	0.00383	CcSEcCtD
Trametinib—Arthralgia—Lovastatin—atherosclerosis	0.00073	0.00383	CcSEcCtD
Trametinib—Hypertension—Ezetimibe—atherosclerosis	0.000726	0.00381	CcSEcCtD
Trametinib—Leukopenia—Simvastatin—atherosclerosis	0.000718	0.00377	CcSEcCtD
Trametinib—Arthralgia—Ezetimibe—atherosclerosis	0.000716	0.00376	CcSEcCtD
Trametinib—Myalgia—Ezetimibe—atherosclerosis	0.000716	0.00376	CcSEcCtD
Trametinib—Dry mouth—Lovastatin—atherosclerosis	0.000714	0.00375	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000711	0.00373	CcSEcCtD
Trametinib—Dysgeusia—Pravastatin—atherosclerosis	0.00071	0.00373	CcSEcCtD
Trametinib—Muscle spasms—Niacin—atherosclerosis	0.000708	0.00371	CcSEcCtD
Trametinib—Constipation—Rosuvastatin—atherosclerosis	0.000706	0.0037	CcSEcCtD
Trametinib—Dry mouth—Ezetimibe—atherosclerosis	0.0007	0.00367	CcSEcCtD
Trametinib—Muscle spasms—Pravastatin—atherosclerosis	0.000697	0.00366	CcSEcCtD
Trametinib—Infection—Lovastatin—atherosclerosis	0.000695	0.00365	CcSEcCtD
Trametinib—Vision blurred—Niacin—atherosclerosis	0.000694	0.00364	CcSEcCtD
Trametinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000685	0.00359	CcSEcCtD
Trametinib—Vision blurred—Pravastatin—atherosclerosis	0.000683	0.00359	CcSEcCtD
Trametinib—Myalgia—Simvastatin—atherosclerosis	0.000682	0.00358	CcSEcCtD
Trametinib—Arthralgia—Simvastatin—atherosclerosis	0.000682	0.00358	CcSEcCtD
Trametinib—Infection—Ezetimibe—atherosclerosis	0.000682	0.00358	CcSEcCtD
Trametinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000675	0.00354	CcSEcCtD
Trametinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000673	0.00353	CcSEcCtD
Trametinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000672	0.00353	CcSEcCtD
Trametinib—Anaemia—Pravastatin—atherosclerosis	0.00067	0.00352	CcSEcCtD
Trametinib—Skin disorder—Ezetimibe—atherosclerosis	0.000666	0.0035	CcSEcCtD
Trametinib—Leukopenia—Niacin—atherosclerosis	0.000659	0.00346	CcSEcCtD
Trametinib—Oedema—Simvastatin—atherosclerosis	0.000654	0.00343	CcSEcCtD
Trametinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000652	0.00342	CcSEcCtD
Trametinib—Infection—Simvastatin—atherosclerosis	0.00065	0.00341	CcSEcCtD
Trametinib—Leukopenia—Pravastatin—atherosclerosis	0.000649	0.00341	CcSEcCtD
Trametinib—Cough—Niacin—atherosclerosis	0.000642	0.00337	CcSEcCtD
Trametinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000641	0.00336	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000637	0.00334	CcSEcCtD
Trametinib—Insomnia—Lovastatin—atherosclerosis	0.000633	0.00332	CcSEcCtD
Trametinib—Cough—Pravastatin—atherosclerosis	0.000632	0.00332	CcSEcCtD
Trametinib—Myalgia—Niacin—atherosclerosis	0.000627	0.00329	CcSEcCtD
Trametinib—Arthralgia—Niacin—atherosclerosis	0.000627	0.00329	CcSEcCtD
Trametinib—Hypertension—Pravastatin—atherosclerosis	0.000626	0.00328	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000625	0.00328	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000622	0.00327	CcSEcCtD
Trametinib—Insomnia—Ezetimibe—atherosclerosis	0.000621	0.00326	CcSEcCtD
Trametinib—Arthralgia—Pravastatin—atherosclerosis	0.000617	0.00324	CcSEcCtD
Trametinib—Myalgia—Pravastatin—atherosclerosis	0.000617	0.00324	CcSEcCtD
Trametinib—Dry mouth—Niacin—atherosclerosis	0.000613	0.00322	CcSEcCtD
Trametinib—Decreased appetite—Lovastatin—atherosclerosis	0.000608	0.00319	CcSEcCtD
Trametinib—Fatigue—Lovastatin—atherosclerosis	0.000603	0.00317	CcSEcCtD
Trametinib—Oedema—Niacin—atherosclerosis	0.000601	0.00315	CcSEcCtD
Trametinib—Constipation—Lovastatin—atherosclerosis	0.000598	0.00314	CcSEcCtD
Trametinib—Decreased appetite—Ezetimibe—atherosclerosis	0.000596	0.00313	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000596	0.00313	CcSEcCtD
Trametinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000592	0.00311	CcSEcCtD
Trametinib—Asthenia—Rosuvastatin—atherosclerosis	0.000592	0.00311	CcSEcCtD
Trametinib—Insomnia—Simvastatin—atherosclerosis	0.000592	0.00311	CcSEcCtD
Trametinib—Oedema—Pravastatin—atherosclerosis	0.000592	0.0031	CcSEcCtD
Trametinib—Fatigue—Ezetimibe—atherosclerosis	0.000591	0.0031	CcSEcCtD
Trametinib—Infection—Pravastatin—atherosclerosis	0.000588	0.00308	CcSEcCtD
Trametinib—Constipation—Ezetimibe—atherosclerosis	0.000587	0.00308	CcSEcCtD
Trametinib—Pruritus—Rosuvastatin—atherosclerosis	0.000584	0.00306	CcSEcCtD
Trametinib—Skin disorder—Niacin—atherosclerosis	0.000584	0.00306	CcSEcCtD
Trametinib—Hyperhidrosis—Niacin—atherosclerosis	0.000581	0.00305	CcSEcCtD
Trametinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000579	0.00304	CcSEcCtD
Trametinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000572	0.003	CcSEcCtD
Trametinib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000572	0.003	CcSEcCtD
Trametinib—Decreased appetite—Simvastatin—atherosclerosis	0.000569	0.00299	CcSEcCtD
Trametinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000565	0.00296	CcSEcCtD
Trametinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000565	0.00296	CcSEcCtD
Trametinib—Fatigue—Simvastatin—atherosclerosis	0.000564	0.00296	CcSEcCtD
Trametinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000561	0.00294	CcSEcCtD
Trametinib—Constipation—Simvastatin—atherosclerosis	0.000559	0.00294	CcSEcCtD
Trametinib—Abdominal pain—Lovastatin—atherosclerosis	0.000553	0.0029	CcSEcCtD
Trametinib—Body temperature increased—Lovastatin—atherosclerosis	0.000553	0.0029	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000547	0.00287	CcSEcCtD
Trametinib—Dizziness—Rosuvastatin—atherosclerosis	0.000546	0.00286	CcSEcCtD
Trametinib—Insomnia—Niacin—atherosclerosis	0.000543	0.00285	CcSEcCtD
Trametinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000542	0.00285	CcSEcCtD
Trametinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000542	0.00285	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000539	0.00283	CcSEcCtD
Trametinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000535	0.00281	CcSEcCtD
Trametinib—Insomnia—Pravastatin—atherosclerosis	0.000535	0.00281	CcSEcCtD
Trametinib—Decreased appetite—Niacin—atherosclerosis	0.000522	0.00274	CcSEcCtD
Trametinib—Rash—Rosuvastatin—atherosclerosis	0.00052	0.00273	CcSEcCtD
Trametinib—Dermatitis—Rosuvastatin—atherosclerosis	0.00052	0.00273	CcSEcCtD
Trametinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000519	0.00272	CcSEcCtD
Trametinib—Abdominal pain—Simvastatin—atherosclerosis	0.000517	0.00271	CcSEcCtD
Trametinib—Body temperature increased—Simvastatin—atherosclerosis	0.000517	0.00271	CcSEcCtD
Trametinib—Headache—Rosuvastatin—atherosclerosis	0.000517	0.00271	CcSEcCtD
Trametinib—Decreased appetite—Pravastatin—atherosclerosis	0.000514	0.0027	CcSEcCtD
Trametinib—Fatigue—Pravastatin—atherosclerosis	0.00051	0.00268	CcSEcCtD
Trametinib—Constipation—Pravastatin—atherosclerosis	0.000506	0.00265	CcSEcCtD
Trametinib—Asthenia—Lovastatin—atherosclerosis	0.000502	0.00263	CcSEcCtD
Trametinib—Pruritus—Lovastatin—atherosclerosis	0.000495	0.0026	CcSEcCtD
Trametinib—Asthenia—Ezetimibe—atherosclerosis	0.000492	0.00258	CcSEcCtD
Trametinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000491	0.00258	CcSEcCtD
Trametinib—Nausea—Rosuvastatin—atherosclerosis	0.00049	0.00257	CcSEcCtD
Trametinib—Pruritus—Ezetimibe—atherosclerosis	0.000485	0.00255	CcSEcCtD
Trametinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000484	0.00254	CcSEcCtD
Trametinib—Diarrhoea—Lovastatin—atherosclerosis	0.000479	0.00251	CcSEcCtD
Trametinib—Body temperature increased—Niacin—atherosclerosis	0.000475	0.00249	CcSEcCtD
Trametinib—Abdominal pain—Niacin—atherosclerosis	0.000475	0.00249	CcSEcCtD
Trametinib—Asthenia—Simvastatin—atherosclerosis	0.000469	0.00246	CcSEcCtD
Trametinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000469	0.00246	CcSEcCtD
Trametinib—Body temperature increased—Pravastatin—atherosclerosis	0.000468	0.00245	CcSEcCtD
Trametinib—Abdominal pain—Pravastatin—atherosclerosis	0.000468	0.00245	CcSEcCtD
Trametinib—Pruritus—Simvastatin—atherosclerosis	0.000463	0.00243	CcSEcCtD
Trametinib—Dizziness—Lovastatin—atherosclerosis	0.000463	0.00243	CcSEcCtD
Trametinib—Dizziness—Ezetimibe—atherosclerosis	0.000454	0.00238	CcSEcCtD
Trametinib—Diarrhoea—Simvastatin—atherosclerosis	0.000448	0.00235	CcSEcCtD
Trametinib—Vomiting—Lovastatin—atherosclerosis	0.000445	0.00233	CcSEcCtD
Trametinib—Rash—Lovastatin—atherosclerosis	0.000441	0.00231	CcSEcCtD
Trametinib—Dermatitis—Lovastatin—atherosclerosis	0.000441	0.00231	CcSEcCtD
Trametinib—Headache—Lovastatin—atherosclerosis	0.000438	0.0023	CcSEcCtD
Trametinib—Vomiting—Ezetimibe—atherosclerosis	0.000436	0.00229	CcSEcCtD
Trametinib—Dizziness—Simvastatin—atherosclerosis	0.000433	0.00227	CcSEcCtD
Trametinib—Rash—Ezetimibe—atherosclerosis	0.000433	0.00227	CcSEcCtD
Trametinib—Dermatitis—Ezetimibe—atherosclerosis	0.000432	0.00227	CcSEcCtD
Trametinib—Asthenia—Niacin—atherosclerosis	0.000431	0.00226	CcSEcCtD
Trametinib—Headache—Ezetimibe—atherosclerosis	0.00043	0.00226	CcSEcCtD
Trametinib—Pruritus—Niacin—atherosclerosis	0.000425	0.00223	CcSEcCtD
Trametinib—Asthenia—Pravastatin—atherosclerosis	0.000424	0.00223	CcSEcCtD
Trametinib—Pruritus—Pravastatin—atherosclerosis	0.000418	0.0022	CcSEcCtD
Trametinib—Vomiting—Simvastatin—atherosclerosis	0.000416	0.00218	CcSEcCtD
Trametinib—Nausea—Lovastatin—atherosclerosis	0.000415	0.00218	CcSEcCtD
Trametinib—Rash—Simvastatin—atherosclerosis	0.000413	0.00217	CcSEcCtD
Trametinib—Dermatitis—Simvastatin—atherosclerosis	0.000412	0.00216	CcSEcCtD
Trametinib—Diarrhoea—Niacin—atherosclerosis	0.000411	0.00216	CcSEcCtD
Trametinib—Headache—Simvastatin—atherosclerosis	0.00041	0.00215	CcSEcCtD
Trametinib—Nausea—Ezetimibe—atherosclerosis	0.000408	0.00214	CcSEcCtD
Trametinib—Diarrhoea—Pravastatin—atherosclerosis	0.000405	0.00212	CcSEcCtD
Trametinib—Dizziness—Niacin—atherosclerosis	0.000397	0.00209	CcSEcCtD
Trametinib—Dizziness—Pravastatin—atherosclerosis	0.000391	0.00205	CcSEcCtD
Trametinib—Nausea—Simvastatin—atherosclerosis	0.000389	0.00204	CcSEcCtD
Trametinib—Vomiting—Niacin—atherosclerosis	0.000382	0.002	CcSEcCtD
Trametinib—Rash—Niacin—atherosclerosis	0.000379	0.00199	CcSEcCtD
Trametinib—Dermatitis—Niacin—atherosclerosis	0.000378	0.00199	CcSEcCtD
Trametinib—Headache—Niacin—atherosclerosis	0.000376	0.00198	CcSEcCtD
Trametinib—Vomiting—Pravastatin—atherosclerosis	0.000376	0.00197	CcSEcCtD
Trametinib—Rash—Pravastatin—atherosclerosis	0.000373	0.00196	CcSEcCtD
Trametinib—Dermatitis—Pravastatin—atherosclerosis	0.000373	0.00196	CcSEcCtD
Trametinib—Headache—Pravastatin—atherosclerosis	0.000371	0.00194	CcSEcCtD
Trametinib—Nausea—Niacin—atherosclerosis	0.000357	0.00187	CcSEcCtD
Trametinib—Nausea—Pravastatin—atherosclerosis	0.000351	0.00184	CcSEcCtD
Trametinib—MAP2K2—Immune System—TLR4—atherosclerosis	2.88e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PDGFB—atherosclerosis	2.87e-05	0.000106	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.87e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—atherosclerosis	2.86e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—atherosclerosis	2.85e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—F2—atherosclerosis	2.84e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PDGFB—atherosclerosis	2.84e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—atherosclerosis	2.83e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—atherosclerosis	2.81e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NFKB1—atherosclerosis	2.81e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—atherosclerosis	2.8e-05	0.000103	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.8e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KNG1—atherosclerosis	2.77e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ICAM1—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOA2—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLA2G2A—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALOX15—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALOX5AP—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK8—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGTR1—atherosclerosis	2.76e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MAPK3—atherosclerosis	2.73e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTHFR—atherosclerosis	2.73e-05	0.0001	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCG5—atherosclerosis	2.73e-05	0.0001	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.72e-05	0.0001	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLTP—atherosclerosis	2.72e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CG—atherosclerosis	2.72e-05	9.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOE—atherosclerosis	2.71e-05	9.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL2—atherosclerosis	2.7e-05	9.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TLR4—atherosclerosis	2.69e-05	9.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CAV1—atherosclerosis	2.69e-05	9.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PLG—atherosclerosis	2.69e-05	9.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOA1—atherosclerosis	2.68e-05	9.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PDGFB—atherosclerosis	2.65e-05	9.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—atherosclerosis	2.65e-05	9.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—atherosclerosis	2.64e-05	9.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LPA—atherosclerosis	2.63e-05	9.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KNG1—atherosclerosis	2.59e-05	9.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ICAM1—atherosclerosis	2.58e-05	9.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGTR1—atherosclerosis	2.58e-05	9.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MAPK3—atherosclerosis	2.58e-05	9.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BGN—atherosclerosis	2.55e-05	9.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SOCS3—atherosclerosis	2.54e-05	9.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOE—atherosclerosis	2.54e-05	9.33e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.53e-05	9.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL2—atherosclerosis	2.53e-05	9.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—atherosclerosis	2.53e-05	9.29e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOA5—atherosclerosis	2.52e-05	9.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CAV1—atherosclerosis	2.52e-05	9.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PLG—atherosclerosis	2.51e-05	9.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOA1—atherosclerosis	2.51e-05	9.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—atherosclerosis	2.47e-05	9.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP3—atherosclerosis	2.46e-05	9.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.45e-05	9.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF2—atherosclerosis	2.45e-05	8.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLA2G1B—atherosclerosis	2.43e-05	8.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MAPK3—atherosclerosis	2.41e-05	8.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.4e-05	8.83e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.38e-05	8.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SOCS3—atherosclerosis	2.38e-05	8.74e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.37e-05	8.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOB—atherosclerosis	2.37e-05	8.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—atherosclerosis	2.37e-05	8.69e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LTA4H—atherosclerosis	2.36e-05	8.67e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG8—atherosclerosis	2.36e-05	8.67e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALOX5—atherosclerosis	2.35e-05	8.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EDN1—atherosclerosis	2.34e-05	8.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL5—atherosclerosis	2.32e-05	8.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—INS—atherosclerosis	2.32e-05	8.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP3—atherosclerosis	2.3e-05	8.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF2—atherosclerosis	2.29e-05	8.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LPL—atherosclerosis	2.27e-05	8.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOB—atherosclerosis	2.22e-05	8.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PRKCG—atherosclerosis	2.2e-05	8.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EDN1—atherosclerosis	2.19e-05	8.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL5—atherosclerosis	2.17e-05	7.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—INS—atherosclerosis	2.17e-05	7.97e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.17e-05	7.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SPP1—atherosclerosis	2.15e-05	7.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—atherosclerosis	2.14e-05	7.86e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—atherosclerosis	2.13e-05	7.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SERPINE1—atherosclerosis	2.13e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LPL—atherosclerosis	2.12e-05	7.79e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NAMPT—atherosclerosis	2.1e-05	7.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNG—atherosclerosis	2.1e-05	7.72e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.09e-05	7.69e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LIPC—atherosclerosis	2.09e-05	7.69e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOC3—atherosclerosis	2.08e-05	7.64e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LDLR—atherosclerosis	2.07e-05	7.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PRKCG—atherosclerosis	2.06e-05	7.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS3—atherosclerosis	2.03e-05	7.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CETP—atherosclerosis	2.02e-05	7.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SPP1—atherosclerosis	2.01e-05	7.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—atherosclerosis	2e-05	7.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—atherosclerosis	2e-05	7.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SERPINE1—atherosclerosis	1.99e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDGFB—atherosclerosis	1.99e-05	7.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—atherosclerosis	1.97e-05	7.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—atherosclerosis	1.96e-05	7.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGT—atherosclerosis	1.94e-05	7.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SCARB1—atherosclerosis	1.93e-05	7.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS3—atherosclerosis	1.9e-05	6.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOE—atherosclerosis	1.9e-05	6.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LEP—atherosclerosis	1.9e-05	6.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—atherosclerosis	1.88e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CAV1—atherosclerosis	1.88e-05	6.92e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.88e-05	6.91e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOA1—atherosclerosis	1.88e-05	6.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—atherosclerosis	1.87e-05	6.88e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.86e-05	6.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—atherosclerosis	1.86e-05	6.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFB—atherosclerosis	1.86e-05	6.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—atherosclerosis	1.84e-05	6.76e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMGCR—atherosclerosis	1.82e-05	6.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGT—atherosclerosis	1.81e-05	6.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—atherosclerosis	1.81e-05	6.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—F2—atherosclerosis	1.79e-05	6.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—atherosclerosis	1.78e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOE—atherosclerosis	1.78e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—atherosclerosis	1.76e-05	6.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CAV1—atherosclerosis	1.76e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOA1—atherosclerosis	1.76e-05	6.46e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FABP4—atherosclerosis	1.75e-05	6.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LCAT—atherosclerosis	1.75e-05	6.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—atherosclerosis	1.75e-05	6.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NFKB1—atherosclerosis	1.75e-05	6.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—atherosclerosis	1.74e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—atherosclerosis	1.74e-05	6.39e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOA4—atherosclerosis	1.72e-05	6.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK8—atherosclerosis	1.72e-05	6.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—atherosclerosis	1.71e-05	6.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—atherosclerosis	1.7e-05	6.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.69e-05	6.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—F2—atherosclerosis	1.68e-05	6.16e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.65e-05	6.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—atherosclerosis	1.64e-05	6.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NFKB1—atherosclerosis	1.64e-05	6.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCA1—atherosclerosis	1.63e-05	5.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—atherosclerosis	1.63e-05	5.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—INS—atherosclerosis	1.62e-05	5.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK8—atherosclerosis	1.61e-05	5.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—atherosclerosis	1.6e-05	5.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL2—atherosclerosis	1.6e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—atherosclerosis	1.57e-05	5.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—atherosclerosis	1.57e-05	5.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.56e-05	5.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—atherosclerosis	1.54e-05	5.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—INS—atherosclerosis	1.52e-05	5.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—atherosclerosis	1.5e-05	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL2—atherosclerosis	1.49e-05	5.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—atherosclerosis	1.49e-05	5.48e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOA2—atherosclerosis	1.48e-05	5.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.48e-05	5.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.48e-05	5.44e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.48e-05	5.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—atherosclerosis	1.47e-05	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—atherosclerosis	1.47e-05	5.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.46e-05	5.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—atherosclerosis	1.45e-05	5.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—atherosclerosis	1.42e-05	5.23e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LPA—atherosclerosis	1.41e-05	5.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—atherosclerosis	1.4e-05	5.16e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMOX1—atherosclerosis	1.4e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—atherosclerosis	1.39e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—atherosclerosis	1.39e-05	5.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BGN—atherosclerosis	1.37e-05	5.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—atherosclerosis	1.36e-05	4.99e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOA5—atherosclerosis	1.35e-05	4.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—atherosclerosis	1.34e-05	4.94e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOB—atherosclerosis	1.34e-05	4.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—atherosclerosis	1.33e-05	4.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.3e-05	4.79e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—atherosclerosis	1.3e-05	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—atherosclerosis	1.3e-05	4.76e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LPL—atherosclerosis	1.28e-05	4.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—atherosclerosis	1.26e-05	4.64e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.26e-05	4.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—atherosclerosis	1.26e-05	4.62e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPX1—atherosclerosis	1.25e-05	4.58e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CD36—atherosclerosis	1.21e-05	4.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—atherosclerosis	1.2e-05	4.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—atherosclerosis	1.18e-05	4.34e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—atherosclerosis	1.15e-05	4.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—atherosclerosis	1.14e-05	4.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKB1—atherosclerosis	1.13e-05	4.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.13e-05	4.15e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARA—atherosclerosis	1.13e-05	4.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—atherosclerosis	1.12e-05	4.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.12e-05	4.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.12e-05	4.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK8—atherosclerosis	1.11e-05	4.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.11e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—atherosclerosis	1.11e-05	4.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—atherosclerosis	1.1e-05	4.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AGT—atherosclerosis	1.09e-05	4.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CETP—atherosclerosis	1.08e-05	3.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOE—atherosclerosis	1.07e-05	3.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—atherosclerosis	1.07e-05	3.93e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAV1—atherosclerosis	1.06e-05	3.9e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOA1—atherosclerosis	1.06e-05	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKB1—atherosclerosis	1.06e-05	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK8—atherosclerosis	1.04e-05	3.82e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.04e-05	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—atherosclerosis	1.04e-05	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—atherosclerosis	1.03e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—atherosclerosis	1.03e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—atherosclerosis	1.02e-05	3.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—atherosclerosis	1.01e-05	3.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—atherosclerosis	1.01e-05	3.72e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	9.79e-06	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—atherosclerosis	9.7e-06	3.57e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	9.65e-06	3.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—atherosclerosis	9.59e-06	3.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—atherosclerosis	9.5e-06	3.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—atherosclerosis	9.48e-06	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—atherosclerosis	9.47e-06	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—atherosclerosis	9.41e-06	3.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—atherosclerosis	9.34e-06	3.43e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—atherosclerosis	9.32e-06	3.42e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—INS—atherosclerosis	9.14e-06	3.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—atherosclerosis	9.08e-06	3.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—atherosclerosis	8.81e-06	3.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—atherosclerosis	8.74e-06	3.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	8.73e-06	3.21e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—atherosclerosis	8.38e-06	3.08e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—atherosclerosis	8.01e-06	2.95e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	7.49e-06	2.75e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—atherosclerosis	7.33e-06	2.69e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOB—atherosclerosis	7.17e-06	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—atherosclerosis	7.09e-06	2.61e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	6.98e-06	2.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LPL—atherosclerosis	6.85e-06	2.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX1—atherosclerosis	6.68e-06	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—atherosclerosis	6.64e-06	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—atherosclerosis	6.54e-06	2.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CD36—atherosclerosis	6.51e-06	2.39e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.17e-06	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—atherosclerosis	6.12e-06	2.25e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARA—atherosclerosis	6.05e-06	2.22e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AGT—atherosclerosis	5.86e-06	2.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOE—atherosclerosis	5.74e-06	2.11e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAV1—atherosclerosis	5.69e-06	2.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOA1—atherosclerosis	5.68e-06	2.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.18e-06	1.9e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—atherosclerosis	5e-06	1.84e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—INS—atherosclerosis	4.91e-06	1.8e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—atherosclerosis	4.5e-06	1.65e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—atherosclerosis	4.3e-06	1.58e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.93e-06	1.45e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—atherosclerosis	3.68e-06	1.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.98e-06	7.27e-06	CbGpPWpGaD
